Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.
Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.
Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and ...
Women aged 60 years or older had a 32% higher likelihood of CRSsNP diagnosis (OR 1.32). Women had a 37% lower chance of being ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback